Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by ChiefBroncoon Feb 29, 2020 6:53pm

41 Views

Post# 30751880

RE:Kalytera is on the verge of legacy

ChiefBronco wrote:
1 - First to have Fda approved GVHD treatment 2- Life threatening condition 3- Urgent unmet need for treatment 4- 408 million a year and up to 1.3 billion a year by 2027 No other company on the market is positioned this way, plus thats only the GVHD not to mention there pain drug there working on. Anyway Im holding this gem for a couple a years for sure or until a big pharma company buy us out. For me this is a no brainer, Hold for profit. Cheers

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity